Aspira Pathlab & Diagnostics' Stock Reaches 52-Week High, Outperforms Sensex in Past Year
Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has seen a surge in its stock price, reaching a 52-week high of Rs.62.51 on November 11, 2024. The stock has been on a consecutive gain for the past 3 days and is trading higher than its moving averages, indicating a positive trend. The company has outperformed the Sensex in the past year, showcasing its strong performance and potential for growth in the healthcare industry.
Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has recently seen a surge in its stock price. On November 11, 2024, the company's stock reached a 52-week high of Rs.62.51. This has caught the attention of investors and market analysts, with MarketsMOJO giving a 'Sell' call for the stock.
The stock's performance today has been in line with the sector, but it has been on a consecutive gain for the past 3 days, with a rise of 8.52% during this period. Aspira Pathlab's stock is also trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend.
In the past year, Aspira Pathlab & Diagnostics has outperformed the Sensex with a 62.77% return, while the Sensex has only seen a 22.44% increase. This showcases the company's strong performance and potential for growth in the healthcare industry.
Aspira Pathlab & Diagnostics is a company that provides essential diagnostic and pathology services to hospitals and healthcare facilities. With its recent stock price surge and positive performance, the company is poised for further success in the future.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
